Evidence map›Paper›PMID 25846329›Full record

Trial reportThe American journal on addictions2015

No evidence for reduction of opioid-withdrawal symptoms by cannabis smoking during a methadone dose taper.

David H Epstein, Kenzie L Preston

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The American journal on addictions, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 2 pooled it
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. The endocannabinoid system and breathing.Frontiers in neuroscience · 2023
    Review
  7. Article
  8. The impact of marijuana use on cocaine use outcomes among patients in methadone maintenance treatment across five trials of contingency management.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. Choosing Between a Rock and the Pot Place.Cannabis and cannabinoid research · 2021
    Article
  13. Article
  14. Review
  15. Review
  16. Emerging Evidence for Cannabis' Role in Opioid Use Disorder.Cannabis and cannabinoid research · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

David H EpsteinTreatment Section, Clinical Pharmacology & Therapeutics Branch, Intramural Research Branch of the National Institute on Drug Abuse, Baltimore, Maryland.
Kenzie L Preston
National Institute on Drug Abuse · US

Funding

Prevention of Relapse in AddictionZIADA000536 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI PRESTON, KENZIE · 2009 to 2018
$9.5M
Evaluation Of Treatments Of Opioid And Cocaine DependenceZIADA000175 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI PRESTON, KENZIE · 2009 to 2016
$7.4M
Intramural NIH HHS Z99 DA999999
6 · The paper itself

Abstract

BACKGROUND AND

objectivesTo support medication development with cannabinoids, smoked cannabis has been said to alleviate symptoms of opioid withdrawal. We evaluated that hypothesis.

methodsWe analyzed data from the methadone-taper phase of a clinical trial we had conducted. Participants were 116 outpatient heroin and cocaine users (of whom 46 were also cannabis users) who stayed for the 10-week taper. Main outcome measures were weekly urine screens for cannabinoids, plus every-two-week assessments of opioid-withdrawal symptoms.

resultsOpioid-withdrawal scores did not differ overall between users and nonusers of cannabis. In a lagged analysis in the 46 users, there was a slight (not statistically significant) indication that weeks of higher opiate-withdrawal symptoms preceded weeks of cannabis use (effect-size r = .20, 95% CI -.10 to .46, p = .52). Even if this finding is taken to suggest self-medication with cannabis, a lagged analysis in the other temporal direction showed no indication that cannabis use predicted lower opiate-withdrawal symptoms the next week (effect-size r = .01, 95% CI -.28 to .30, p = .69). These findings persisted in sensitivity analyses controlling for each of 17 potential confounds. DISCUSSION AND

conclusionWith our findings, the clinical evidence for smoked cannabis as a reducer of opioid-withdrawal symptoms moves slightly further from "inconclusive" or "mixed" and closer to negative, at least in the context of a methadone dose taper like the one used here. SCIENTIFIC SIGNIFICANCE: This finding may remove one rationale for medication development using cannabinoids to treat opioid withdrawal, but leaves other rationales intact.

Indexed as

Medical MarijuanaAdultCocaine-Related DisordersDose-Response Relationship, DrugDrug Therapy, CombinationFemaleHeroin DependenceHumansMaleMethadoneMiddle AgedNarcoticsSubstance Withdrawal SyndromeYoung AdultMedical MarijuanaMethadoneNarcotics

Identifiers

PMID25846329
PMCPMC5576177
OpenAlexW1892729505

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.